Physician profile
Osama H Said
NPI 1235182858
$596,630.17
in general payments reported to CMS, 2019-2025
13 companies · $137K in 2025
The $137K reported for 2025 was more than what 99% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $163 · 2020: $9,285 · 2021: $20K · 2022: $51K · 2023: $146K · 2024: $233K · 2025: $137K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $308K · Consulting Fee: $129K · Travel and Lodging: $67K · Food and Beverage: $12K · Education: $17.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $308,200.00 |
| Consulting Fee | $128,962.50 |
| Travel and Lodging | $66,603.07 |
| Food and Beverage | $12,252.07 |
| Education | $17.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bausch & Lomb Americas INC. | $555,643.56 | 2022-2025 | Infuse, Infuse Multifocal, Infuse Svs |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $29,343.69 | 2019-2021 | |
| Atlas Ocular, INC | $11,200.00 | 2024-2025 | |
| Alcon Vision LLC | $138.83 | 2019-2025 | Rocklatan, Rhopressa, Precision 1 |
| Coopervision INC. | $56.25 | 2019 | |
| Sun Pharmaceutical Industries INC. | $53.87 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $48.12 | 2022-2023 | |
| Tarsus Pharmaceuticals, INC. | $31.98 | 2024 | Xdemvy |
| Allergan, INC. | $31.88 | 2021 | |
| Abbvie INC. | $29.83 | 2023 | |
| Biotissue Holdings INC. | $20.79 | 2024 | |
| Kala Pharmaceuticals, INC. | $15.85 | 2021 | |
| Maculogix, INC. | $15.52 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Osama Said listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.